MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC

Hao,Peng; Kang,Bo; Yao,Guoqing; Hao,Wenqi; Ma,Feihong

doi:10.3892/ol.2018.7877

MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC

Authors:
- Peng Hao
- Bo Kang
- Guoqing Yao
- Wenqi Hao
- Feihong Ma
View Affiliations

Affiliations: Department of Urology, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China, Central Sterile Supply Department, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Surgery 1, The 224th Hospital of Chinese People's Liberation Army, Jiamusi, Heilongjiang 154002, P.R. China, Department of Clinical Medicine, School of Clinical Medicine, Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China, Department of Interventional Radiology, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/ol.2018.7877
Pages: 4323-4329
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of microRNAs (miRNAs/miRs) is frequently associated with cancer progression. Altered expression of miR‑211 has been observed in various types of human cancer; however, its expression and role in prostate cancer (PCa) remains unknown. In the present study, the expression of miR‑211 in PCa cell lines and tissues was measured by reverse transcription‑quantitative PCR (qPCR), revealing that miR‑211 was downregulated in PCa cell lines and tissues. Further analysis revealed that low miR‑211 was associated with the tumor stage and Gleason score. With the assistance of miR‑211 mimics and inhibitor, it was also revealed that the overexpression of miR‑211 could inhibit PCa cell proliferation in vitro. Conversely, downregulated miR‑211 expression promotes PCa cell proliferation. In addition, the secreted protein acidic and rich in cysteine (SPARC) was identified as a target of miR‑211 in the PCa cell lines, and SPARC expression was inversely associated with miR‑211. In conclusion, it was demonstrated that the miR‑211 expression was downregulated in PCa cell lines and tissues. Additionally, miR‑211 could inhibit PCa cell proliferation partially by downregulating SPARC. Therefore, miR‑211 may be a potential therapeutic target for PCa treatment in the future.

View Figures

View References

1	Hashimoto Y, Shiina M, Kato T, Yamamura S, Tanaka Y, Majid S, Saini S, Shahryari V, Kulkarni P, Desgupta P, et al: The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget. 8:16581–16593. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Hu J, He J, Kuang Y, Wang Z, Sun Z, Zhu H and Liu X: Expression and significance of 90K/Mac-2BP in prostate cancer. Exp Ther Med. 5:181–184. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
5	Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G and Hartwell L: The case for early detection. Nat Rev Cancer. 3:243–252. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lee RC, Feinbaum RL and Ambros V: The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
8	Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
10	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
11	Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
12	Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS and Cheng AJ: miR-196, an emerging cancer biomarker for digestive tract cancers. J Cancer. 7:650–655. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lee H, Lee S, Bae H, Kang HS and Kim SJ: Genome-wide identification of target genes for miR-204 and miR-211 identifies their proliferation stimulatory role in breast cancer cells. Sci Rep. 6:252872016. View Article : Google Scholar : PubMed/NCBI
14	Wang CY, Hua L, Sun J, Yao KH, Chen JT, Zhang JJ and Hu JH: MiR-211 inhibits cell proliferation and invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp Pathol. 8:14013–14020. 2015.PubMed/NCBI
15	Jiang G, Cui Y, Yu X, Wu Z, Ding G and Cao L: miR-211 suppresses hepatocellular carcinoma by downregulating SATB2. Oncotarget. 6:9457–9466. 2015.PubMed/NCBI
16	Deng B, Qu L, Li J, Fang J, Yang S, Cao Z, Mei Z and Sun X: MiRNA-211 suppresses cell proliferation, migration and invasion by targeting SPARC in human hepatocellular carcinoma. Sci Rep. 6:266792016. View Article : Google Scholar : PubMed/NCBI
17	Xia B, Yang S, Liu T and Lou G: miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015. View Article : Google Scholar : PubMed/NCBI
18	Ye L, Wang H and Liu B: miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumor Biol. 37:1151–1157. 2016. View Article : Google Scholar
19	Motamed K: SPARC (osteonectin/BM-40). Int J Biochem Cell Biol. 31:1363–1366. 1999. View Article : Google Scholar : PubMed/NCBI
20	Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, Kitagawa Y, Miwa S, Kumaki M, Keller ET and Namiki M: Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. Prostate. 73:1159–1170. 2013. View Article : Google Scholar : PubMed/NCBI
21	Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF and Rich JN: Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem. 279:52200–52209. 2004. View Article : Google Scholar : PubMed/NCBI
22	Thomas R, True LD, Bassuk JA, Lange PH and Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 6:1140–1149. 2000.PubMed/NCBI
23	Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 16:260–268. 2010. View Article : Google Scholar : PubMed/NCBI
24	Massi D, Franchi A, Borgognoni L, Reali UM and Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 30:339–344. 1999. View Article : Google Scholar : PubMed/NCBI
25	Sharma S, Xing F, Liu Y, Wu K, Said N, Pochampally R, Shizawa Y, Lin HK, Balaji KC and Watabe K: Secreted Protein Acidic and Rich in Cysteine (SPARC) mediates metastatic dormancy of prostate cancer in bone. J Biol Chem. 291:19351–19363. 2016. View Article : Google Scholar : PubMed/NCBI
26	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adensines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
29	Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW and Kavanagh BD: The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 32:707–713. 2014. View Article : Google Scholar : PubMed/NCBI
30	Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, et al: Prognostic value of PTEN loss in men with conservatively managed localized prostate cancer. Br J Cancer. 108:2582–2589. 2013. View Article : Google Scholar : PubMed/NCBI
31	Noh BJ, Sung JY, Kim YW, Chang SG and Park YK: Prognostic value of ERG, PTEN, CRISPR3 and SPINK1 in predicting biochemical recurrence in prostate cancer. Oncol Lett. 11:3621–3630. 2016. View Article : Google Scholar : PubMed/NCBI
32	Duan K, Ge YC, Zhang XP, Wu SY, Feng JS, Chen SL, Zhang LI, Yuan ZH and Fu CH: miR-34a inhibits cell proliferation in prostate cancer by downregulating of SIRT1 expression. Oncol Lett. 10:3223–3227. 2015. View Article : Google Scholar : PubMed/NCBI
33	Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, deCarvalho AC, Slavin S, et al: MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 4:665–676. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lu C, Liao Z, Cai M and Zhang G: MicroRNA-320a downregulation mediates human liver cancer cell proliferation through the Wnt/β-catenin signaling pathway. Oncol Lett. 13:573–578. 2017. View Article : Google Scholar : PubMed/NCBI